Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Karim Fizazi(Université de Lille), Mika Mustonen(Orion Corporation (United Kingdom)), Peter Langmuir(Endo Pharmaceuticals (United States)), Teuvo L.J. Tammela(Tampere University), Nicholas D. James(Royal Marsden NHS Foundation Trust), Annamari Vuorela(Orion Corporation (United Kingdom)), Vesa Kataja(Kuopio University Hospital), Robert H. Jones(Velindre NHS Trust), Andrew Protheroe(University of Oxford), Tony Elliott(The Christie Hospital), Leena Mattila(University of Turku), Christophe Massard(Institut Gustave Roussy), John Aspegrén(Orion Corporation (Finland)), Jorge A. García(Cleveland Clinic), Petri Bono(Helsinki University Hospital)

The Lancet Oncology

June 25, 2014

Cited by 194

|New England Journal of Medicine|2013|3.3k

|New England Journal of Medicine|2014|3k

|New England Journal of Medicine|2015|2.8k

|New England Journal of Medicine|2012|2.8k

|New England Journal of Medicine|2015|2.2k

Related Papers